HCM
AMBI

Highbridge Capital Management’s Ambit Biosciences Corp AMBI Stock Holding History

Highbridge Capital Management’s Portfolio AMBI Stock Details AMBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-27,738
Closed -$268K – 1418
2013
Q4 		$268K Buy
+27,738
New +$370K ﹤0.01% 881

Other funds holding AMBI

FCMI
Foresite Capital Management I Larkspur, California $21.4M AUM 80.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Highbridge Capital Management's AMBI Position: Q1 2014 in Review

Highbridge Capital Management sold out of Ambit Biosciences Corp (AMBI) in Q1 2014, closing a stake of 27,738 shares — an estimated $268K sold.

Highbridge Capital Management first reported a position in AMBI in Q4 2013 and held it in 1 quarter. The position peaked at $268K in Q4 2013. 46 funds tracked by Wall St. Rank hold AMBI as of Q1 2014.

  • Highbridge Capital Management reported no remaining Ambit Biosciences Corp position as of Q1 2014 after selling out during the quarter.
  • Highbridge Capital Management sold 27,738 Ambit Biosciences Corp shares in Q1 2014, an estimated $268K.
  • Highbridge Capital Management first reported a position in Ambit Biosciences Corp in Q4 2013 and held it in 1 quarter.
  • Highbridge Capital Management's Ambit Biosciences Corp position peaked at $268K in Q4 2013.
  • 46 funds tracked by Wall St. Rank held Ambit Biosciences Corp as of Q1 2014.

Based on Highbridge Capital Management's 13F filing for Q1 2014, filed 16 May 2014.